Articles From: On Track: Exelis ADS-B Program Delivering Benefits Now to OncoMed Pharmaceuticals to Present at the 13th Annual BIO Investor Forum


As the prime contractor responsible for the Federal Aviation Administration’s (FAA) execution of the Automatic Dependent Surveillance-Broadcast (ADS-B) program, Exelis (NYSE: XLS ) is delivering surveillance coverage requirements on budget and on schedule.
Sign-up for On Track: Exelis ADS-B Program Delivering Benefits Now investment picks
2014/11/28
By Marek Fuchs, MarketWatch Things just got unreal, from shaky economic stats to GM deathtraps A sheaf of economic statistics came out over the course of our shortened week and, depending on which you seized upon, the economy looked like either a rising Phoenix or a wounded duck.
Sign-up for On Wall Street, a week of epic fails investment picks
2014/8/28
ADVISORY, Aug.
Sign-up for Once The Musical to Ring The NASDAQ Stock Market Closing Bell investment picks
2014/10/27
Onco360, one of the nation’s largest independent providers of oncology pharmacy services, today announced that Paul Jardina has been named President and Chief Executive Officer.
Sign-up for Onco360 Appoints Paul Jardina as President and Chief Executive Officer investment picks
2014/12/1
Onco360, one of the nation’s largest independent providers of Oncology Pharmacy services, today announced that it has been selected as a limited distribution pharmacy network participant by Pfizer Inc. (“Pfizer”), and can immediately begin dispensing Bosulif ® (bosutinib), Inlyta ® (axitinib), Sutent ® (sunitinib), and Xalkori ® (crizotinib). With the addition of these four medications, Onco360’s industry-leading oncology medication portfolio now comprises nearly 40 limited distribution products.
Sign-up for Onco360 Selected by Pfizer as Limited Distribution Pharmacy Provider; Expands Onco360’s Industry-Leading Portfolio to Nearly 40 Products investment picks
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference investment picks
2014/10/30
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 Conference call to be held on Thursday, October 30, 2014 at 4:30 p.m. Eastern Time Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 investment picks
2014/10/30
Conference call to be held on Thursday, October 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 investment picks
2014/10/20
Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC Canada NewsWire CALGARY , Oct.
Sign-up for Oncolytics Biotech® Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC investment picks
2014/12/2
Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers Canada NewsWire CALGARY , Dec.
Sign-up for Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers investment picks
2014/11/4
CALGARY , Nov.
Sign-up for Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency investment picks
2014/11/6
Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results Canada NewsWire ONCOLYTICS BIOTECH INC.
Sign-up for Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results investment picks
2014/11/6
CALGARY , Nov.
Sign-up for Oncolytics Biotech® Inc. Announces Third Quarter 2014 Results investment picks
REDWOOD CITY, Calif., Aug.
Sign-up for OncoMed Pharmaceuticals Announces Removal of Partial Clinical Hold by the FDA for Vantictumab investment picks
Raises Year-End Cash Balance Guidance to Over $225 Million From $215 Million REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals Announces Third Quarter 2014 Financial and Operating Results investment picks
REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S. investment picks
REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals to Present at Piper Jaffray Healthcare Conference investment picks
REDWOOD CITY, Calif., Oct.
Sign-up for OncoMed Pharmaceuticals to Present at the 13th Annual BIO Investor Forum investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: On Track: Exelis ADS-B Program Delivering Benefits Now to OncoMed Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent